Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 68 citing articles:

Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
Mingyue Cai, Wensou Huang, Jingjun Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 129
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
Xu Yang, Bowen Chen, Yanyu Wang, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 709-719
Open Access | Times Cited: 42
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 30
Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
Shuguang Ju, Chen Zhou, Chongtu Yang, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 47
Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study
Xukun Wu, Lanfang Yang, Yufeng Chen, et al.
EClinicalMedicine (2023) Vol. 67, pp. 102367-102367
Open Access | Times Cited: 25
Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features
Xinhua Zou, Qingyu Xu, Ran You, et al.
Cancer Medicine (2023) Vol. 12, Iss. 10, pp. 11315-11333
Open Access | Times Cited: 24
Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
Lixing Li, Xin Xu, Wentao Wang, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010035-e010035
Open Access | Times Cited: 1
The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
Qiao Ke, Fuli Xin, Huipeng Fang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 37
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma
Yan‐Jun Xiang, Kang Wang, Hongming Yu, et al.
Hepatology Research (2022) Vol. 52, Iss. 8, pp. 721-729
Closed Access | Times Cited: 33
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study
Jiayi Wu, Zhibo Zhang, Jianyin Zhou, et al.
Liver Cancer (2022) Vol. 12, Iss. 3, pp. 229-237
Open Access | Times Cited: 31
The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma
Nicolò Brandi, Matteo Renzulli
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8598-8598
Open Access | Times Cited: 20
Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study
Kang Wang, Hongfei Zhu, Hongming Yu, et al.
Journal of Oncology (2023) Vol. 2023, pp. 1-8
Open Access | Times Cited: 17
Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy
Di Pan, Haonan Liu, Pengfei Qu, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 2, pp. 273-286
Open Access | Times Cited: 7
A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma.
Bengang Wang, X. Hao, Jinshan Yan, et al.
PubMed (2024) Vol. 12, Iss. 3, pp. 225-243
Closed Access | Times Cited: 7
Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma
Sheng Ye, Qing Wang, Haifeng Liu, et al.
British Journal of Radiology (2024) Vol. 97, Iss. 1155, pp. 668-679
Closed Access | Times Cited: 6
Efficacy of TACE Combined with Lenvatinib Plus Sintilimab for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and/or Right Atrium
Shangkun Ning, Xinge Li, Xiangyu Ma, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1511-1525
Open Access | Times Cited: 15
Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study
Jiayi Wu, Jiayi Wu, Yang-Kai Fu, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 5, pp. 3073-3083
Closed Access | Times Cited: 5
Real-world efficacy and safety of durvalumab–tremelimumab as second-line systemic therapy after atezolizumab–bevacizumab in unresectable hepatocellular carcinoma
Ryoichi Miura, Atsushi Ono, Shigeki Yano, et al.
Medicine (2024) Vol. 103, Iss. 34, pp. e39289-e39289
Open Access | Times Cited: 5
Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
Shuguang Ju, Chen Zhou, Junwen Hu, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 20
Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
Jintao Huang, Bin‐Yan Zhong, Nan Jiang, et al.
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 1217-1228
Open Access | Times Cited: 19
Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
Wei-Li Xia, Xiao-Hui Zhao, Yuan Guo, et al.
Clinical and Translational Gastroenterology (2023)
Open Access | Times Cited: 11
Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti–PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics
Jiayi Wu, Junyi Wu, Shuqun Li, et al.
BioScience Trends (2024) Vol. 18, Iss. 1, pp. 42-48
Open Access | Times Cited: 4
Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus
Hongxiao Wu, Xiaoyan Ding, Yawen Xu, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 8, pp. 843-854
Open Access | Times Cited: 4
Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
Junfeng Bu, Zihan Li, Die Hu, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Sintilimab combined with acetaminophen aggravates liver injury through apoptotic and disturbed bile acid pathways
Jianing Qin, Bin Yu, Yuanyuan Zhou, et al.
Toxicology (2025), pp. 154106-154106
Closed Access
Page 1 - Next Page

Scroll to top